Sphingolipids in Cardiovascular Diseases: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Catherine Yang and Version 1 by Carmine Izzo.

Cardiovascular diseases (CVDs) are the leading cause of death and illness in Europe and worldwide, responsible for a staggering 47% of deaths in Europe. There has been increasing evidence pointing to bioactive sphingolipids as drivers of CVDs. Among them, most studies place emphasis on the cardiovascular effect of ceramides and sphingosine-1-phosphate (S1P), reporting correlation between their aberrant expression and CVD risk factors. 

  • sphingolipids
  • cardiovascular diseases
  • cerebrovascular diseases

1. Introduction

Sphingolipids, including sphingosine, ceramide, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate, are bioactive components in cell membranes that participate in and regulate numerous biological processes, such as cell proliferation and survival, maturation, senescence and apoptosis [1,2,3][1][2][3]. Sphingolipids can be synthesized via the de novo synthesis pathway, but they can also be formed through the sphingomyelinase pathway and/or the so-called “salvage” pathway (Figure 1).
Figure 1. Metabolism and structure of sphingolipids and their implication in cardio- and cerebrovascular diseases. Sphingolipid metabolism and structure are illustrated inside the cell. Ceramide is the heart of the sphingolipid metabolic pathway. Ceramide can be synthesized through several steps: (i) de novo synthesis pathway starting from l-serine and palmitoyl-CoA (red); (ii) SMase pathway, through hydrolysis of sphingomyelin (yellow); (iii) salvage pathway, long-chain sphingoid bases are reused to form ceramide through the action of ceramide synthase (green); (iv) or through hydrolysis of glycosphingolipids and sulfatites (azure). Ceramide can also be synthesized from ceramide-1-phosphate through the action of ceramide-1-phosphate phosphatase (blue). The main cardiovascular diseases and risk factors in which sphingolipids may be used as biomarkers are summarized outside the cell. Abbreviations: serine palmitoyl-CoA-acyltransferase (SPT), 3-ketosphinganine reductase (KSR), (dihydro)-ceramide synthase (CerS), ceramide desaturase (DES), ceramide kinase (CK), glucosylceramide synthase (GCS), glucosyl ceramidase (GCase), ceramidase (CDase), sphingosine-1-phosphate lyase (S1P lyase), sphingosine kinase (SK), sphingosine 1-phosphate phosphatase (S1PPase), sphingomyelin (SM) synthase (SMS), sphingomyelinase (SMase).
Over the last decade, growing numbers of studies have highlighted the role of sphingolipids in the pathogenesis of CVDs [4,5,6,7,8,9][4][5][6][7][8][9]. In mice and rats, repression of sphingolipid biosynthesis attenuates cardiometabolic risk factors, including glucose intolerance, insulin resistance, diabetes, hypertension, atherosclerotic plaque development, arterial dysfunction and heart failure (HF) [10,11,12,13,14][10][11][12][13][14]. Data from patients have also indicated associations of tissue and circulating levels of sphingolipids with increased risk of CVDs, including HF, hypertension, metabolic syndrome and coronary artery disease (CAD) [12,15,16,17,18][12][15][16][17][18].

2. Atherosclerosis and Coronary Artery Disease

Sphingolipids, and in particular, ceramide, can contribute to the pathogenesis of atherosclerosis [19], an inflammatory and potentially lethal condition characterized by the generation of atheromatous plaques, consisting of cholesterol and other lipids [20], in medium- and large-sized arteries [21]. Ceramide can be generated from sphingomyelin (SM) via the activation of the de novo synthesis pathway or from sphingomyelinases (SMases). The development of an atherosclerotic lesion involves a large number of proinflammatory cytokines, such as tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) [22], which, along with oxidized low-density lipoprotein (oxLDL), can stimulate ceramide generation via sphingomyelin hydrolysis [23]. In their work, Laulederkind and colleagues [24] demonstrated that C2-ceramid is able to induce interleukin 6 (IL-6) gene expression in human fibroblasts, a cytokine known to be involved in inflammation [25] and for its ability to induce the liver’s production of the greatest predictor of future cardiovascular risk that has direct proinflammatory effects: C-reactive protein [26]. It has also been proven that oxLDL stimulates an enzymatic cascade that includes neutral SMase, ceramidase and sphingosine kinase, thereby promoting the production of S1P to stimulate mitogenesis [27] and proliferation of smooth muscle cells (SMCs) [28[28][29],29], a hallmark of atherosclerotic lesion development. Moreover, Li and collaborators [30] showed that endogenous ceramides contribute to the subendothelial infiltration of oxLDL into the vessel wall.
Deficiency in or pharmacologic inhibition of neutral SMase2 in an Apolipoprotein E (ApoE)-null mouse model resulted in a decrease in atherosclerotic lesions and macrophage infiltration and lipid deposition via a mechanism involving the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway [31]. S1P is also released from activated platelets and interacts with endothelial cells during the atherosclerotic process [32]. It has also been proven that S1P can induce platelet shape change and aggregation [33] and that ceramide stimulates the release of the plasminogen activator inhibitor (PAI-1) [23[23][34][35],34,35], contributing, once again, to a variety of pathophysiological processes, such as thrombosis and atherosclerosis. In line, high endogenous S1P levels exaggerated atherosclerotic lesion development and increased plasma cholesterol levels in ApoE-null mice [36].
As mentioned above, tumor necrosis factor is able to activate a neutral sphingomyelinase [37], causing an increase in ceramide that, during the inflammation process, can act as an intermediate in TNF signaling in endothelial cells [38]. Furthermore, treatment of these cells with a water-soluble synthetic C8-ceramide or sphingomyelinase C led to the evidence that ceramide can induce NF-κB translocation to the nucleus and an increase in surface expression of E-selectin [38], which mediates the interaction of leukocytes with endothelium [39], thus, contributing to the initial stage of the disease. These sphingolipids can also evoke endothelial cell apoptosis [40[40][41][42],41,42], causing plaque erosion and unleashing other complications combined with the atherosclerotic process [23].
Another mechanism involved in the plaque formation induced by sphingolipids is represented by ceramide’s inclination to self-aggregate. It has a primary role in atherosclerosis’s onset since it contributes to the accumulation of LDL rich in this sphingolipid [43,44][43][44]. This notion is also supported by the evidence that ceramide content in LDL present in the atheromatous plaques is significantly higher than the plasma LDL and this sphingolipid was found only in aggregated LDL [45]. Furthermore, ceramide and other sphingolipids’ levels were increased in human atherosclerotic plaques and associated with plaque inflammation and instability [46,47][46][47].
Several clinical trials have highlighted the role of sphingolipids in atherosclerosis, reporting increased plasma concentrations of ceramides, sphingomyelins, sphinganine and sphingosine in patients with CAD [48]. An interesting clinical trial through a large-scale metabolomic analysis on a total of 200 patients tried to identify potential biomarkers for early-stage atherosclerosis. Analyses showed increased levels of 24 metabolites and a decrease in another 18 metabolites. Overall, nine metabolites were found to be suitable as combinatorial biomarkers, with an acceptable diagnostic accuracy [49]. In patients with CAD, the new PCSK9 has also been shown to significantly alter plasma lipidome composition and not only lipoprotein particles (LDL-C). Although the target for CVD prevention remains the lowering of LDL-C, the lipidome represents an asset for cardiovascular risk prediction and modification [50]. Similarly, treatment with fenofibrate showed not only the expected decrease in triglycerides, LDL-C and total cholesterol, but also an independent reduction in ceramide levels and of plasma apoC-II, apoC-III, apoB100 and SMase, with an increase in apoA-II and adiponectin levels [51]. A bi-ethnic angiographic case-control study showed increased plasma levels of SM in patients with coronary artery disease [48]. This was observed in both African-American and white participants, with a multivariate logistic regression analysis independent of other cardiovascular risk factors [48]. Using an unbiased machine learning approach, Poss et al. [52] identified 30 sphingolipids that were significantly elevated in the serum of patients with CAD (n = 462) compared with healthy controls (n = 212). Circulating ceramides were strongly correlated with disease severity since their levels were higher in subjects with CAD severity and major adverse cardia and cerebrovascular events (MACEs) [52,53,54,55][52][53][54][55]. Moreover, elevated levels of specific ceramide species (C16:0, C18:0, C22:0, C24:0 and C24:1) were associated with increased thrombotic risk, adverse CAD incidents and all-cause mortality [8,56,57,58,59,60][8][56][57][58][59][60]. Based on these findings, the authors of the study suggest serum ceramides as powerful biomarkers of CAD that could be useful to improve risk stratification [52].

References

  1. Rosenfeldt, H.M.; Hobson, J.P.; Maceyka, M.; Olivera, A.; Nava, V.E.; Milstien, S.; Spiegel, S. EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. FASEB J. 2001, 15, 2649–2659.
  2. Sharma, N.; He, Q.; Sharma, R.P. Sphingosine kinase activity confers resistance to apoptosis by fumonisin B1 in human embryonic kidney (HEK-293) cells. Chem. Biol. Interact. 2004, 151, 33–42.
  3. Venable, M.E.; Webb-Froehlich, L.M.; Sloan, E.F.; Thomley, J.E. Shift in sphingolipid metabolism leads to an accumulation of ceramide in senescence. Mech. Ageing Dev. 2006, 127, 473–480.
  4. Dumitru, C.A.; Zhang, Y.; Li, X.; Gulbins, E. Ceramide: A novel player in reactive oxygen species-induced signaling? Antioxid Redox Signal 2007, 9, 1535–1540.
  5. Li, X.; Becker, K.A.; Zhang, Y. Ceramide in redox signaling and cardiovascular diseases. Cell Physiol. Biochem. 2010, 26, 41–48.
  6. Levade, T.; Auge, N.; Veldman, R.J.; Cuvillier, O.; Negre-Salvayre, A.; Salvayre, R. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ. Res. 2001, 89, 957–968.
  7. Spijkers, L.J.; van den Akker, R.F.; Janssen, B.J.; Debets, J.J.; De Mey, J.G.; Stroes, E.S.; van den Born, B.J.; Wijesinghe, D.S.; Chalfant, C.E.; MacAleese, L.; et al. Hypertension is associated with marked alterations in sphingolipid biology: A potential role for ceramide. PLoS ONE 2011, 6, e21817.
  8. Laaksonen, R.; Ekroos, K.; Sysi-Aho, M.; Hilvo, M.; Vihervaara, T.; Kauhanen, D.; Suoniemi, M.; Hurme, R.; Marz, W.; Scharnagl, H.; et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur. Heart J. 2016, 37, 1967–1976.
  9. Iqbal, J.; Walsh, M.T.; Hammad, S.M.; Hussain, M.M. Sphingolipids and Lipoproteins in Health and Metabolic Disorders. Trends Endocrinol. Metab. 2017, 28, 506–518.
  10. Holland, W.L.; Brozinick, J.T.; Wang, L.P.; Hawkins, E.D.; Sargent, K.M.; Liu, Y.; Narra, K.; Hoehn, K.L.; Knotts, T.A.; Siesky, A.; et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5, 167–179.
  11. Hojjati, M.R.; Li, Z.; Zhou, H.; Tang, S.; Huan, C.; Ooi, E.; Lu, S.; Jiang, X.C. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 2005, 280, 10284–10289.
  12. Ji, R.; Akashi, H.; Drosatos, K.; Liao, X.; Jiang, H.; Kennel, P.J.; Brunjes, D.L.; Castillero, E.; Zhang, X.; Deng, L.Y.; et al. Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI Insight 2017, 2, e82922.
  13. Zhang, Q.J.; Holland, W.L.; Wilson, L.; Tanner, J.M.; Kearns, D.; Cahoon, J.M.; Pettey, D.; Losee, J.; Duncan, B.; Gale, D.; et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 2012, 61, 1848–1859.
  14. Bharath, L.P.; Ruan, T.; Li, Y.; Ravindran, A.; Wan, X.; Nhan, J.K.; Walker, M.L.; Deeter, L.; Goodrich, R.; Johnson, E.; et al. Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo. Diabetes 2015, 64, 3914–3926.
  15. Lemaitre, R.N.; Yu, C.; Hoofnagle, A.; Hari, N.; Jensen, P.N.; Fretts, A.M.; Umans, J.G.; Howard, B.V.; Sitlani, C.M.; Siscovick, D.S.; et al. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study. Diabetes 2018, 67, 1663–1672.
  16. Anroedh, S.; Hilvo, M.; Akkerhuis, K.M.; Kauhanen, D.; Koistinen, K.; Oemrawsingh, R.; Serruys, P.; van Geuns, R.J.; Boersma, E.; Laaksonen, R.; et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J. Lipid Res. 2018, 59, 1729–1737.
  17. Hilvo, M.; Vasile, V.C.; Donato, L.J.; Hurme, R.; Laaksonen, R. Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification. Front. Endocrinol. 2020, 11, 570628.
  18. Sattler, K.J.; Elbasan, S.; Keul, P.; Elter-Schulz, M.; Bode, C.; Graler, M.H.; Brocker-Preuss, M.; Budde, T.; Erbel, R.; Heusch, G.; et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res. Cardiol. 2010, 105, 821–832.
  19. Symons, J.D.; Abel, E.D. Lipotoxicity contributes to endothelial dysfunction: A focus on the contribution from ceramide. Rev Endocr. Metab. Disord. 2013, 14, 59–68.
  20. Holland, W.L.; Summers, S.A. Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 2008, 29, 381–402.
  21. Falk, E. Pathogenesis of atherosclerosis. J. Am. Coll Cardiol. 2006, 47, C7–C12.
  22. Plutzky, J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am. J. Cardiol. 2001, 88, 10K–15K.
  23. Auge, N.; Negre-Salvayre, A.; Salvayre, R.; Levade, T. Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog. Lipid Res. 2000, 39, 207–229.
  24. Laulederkind, S.J.; Bielawska, A.; Raghow, R.; Hannun, Y.A.; Ballou, L.R. Ceramide induces interleukin 6 gene expression in human fibroblasts. J. Exp. Med. 1995, 182, 599–604.
  25. Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014, 6, a016295.
  26. Blake, G.J.; Ridker, P.M. Novel clinical markers of vascular wall inflammation. Circ. Res. 2001, 89, 763–771.
  27. Auge, N.; Escargueil-Blanc, I.; Lajoie-Mazenc, I.; Suc, I.; Andrieu-Abadie, N.; Pieraggi, M.T.; Chatelut, M.; Thiers, J.C.; Jaffrezou, J.P.; Laurent, G.; et al. Potential role for ceramide in mitogen-activated protein kinase activation and proliferation of vascular smooth muscle cells induced by oxidized low density lipoprotein. J. Biol. Chem. 1998, 273, 12893–12900.
  28. Bornfeldt, K.E.; Graves, L.M.; Raines, E.W.; Igarashi, Y.; Wayman, G.; Yamamura, S.; Yatomi, Y.; Sidhu, J.S.; Krebs, E.G.; Hakomori, S.; et al. Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: Spatial and temporal modulation of PDGF chemotactic signal transduction. J. Cell Biol. 1995, 130, 193–206.
  29. Pyne, S.; Chapman, J.; Steele, L.; Pyne, N.J. Sphingomyelin-derived lipids differentially regulate the extracellular signal-regulated kinase 2 (ERK-2) and c-Jun N-terminal kinase (JNK) signal cascades in airway smooth muscle. Eur. J. Biochem. 1996, 237, 819–826.
  30. Li, W.; Yang, X.; Xing, S.; Bian, F.; Yao, W.; Bai, X.; Zheng, T.; Wu, G.; Jin, S. Endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes its subendothelial retention in vascular wall. Oxid. Med. Cell Longev. 2014, 2014, 823071.
  31. Lallemand, T.; Rouahi, M.; Swiader, A.; Grazide, M.H.; Geoffre, N.; Alayrac, P.; Recazens, E.; Coste, A.; Salvayre, R.; Negre-Salvayre, A.; et al. nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe(-/-) Mice. Arter. Thromb. Vasc. Biol. 2018, 38, 1479–1492.
  32. Yatomi, Y.; Ohmori, T.; Rile, G.; Kazama, F.; Okamoto, H.; Sano, T.; Satoh, K.; Kume, S.; Tigyi, G.; Igarashi, Y.; et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000, 96, 3431–3438.
  33. Yatomi, Y.; Ruan, F.; Hakomori, S.; Igarashi, Y. Sphingosine-1-phosphate: A platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood 1995, 86, 193–202.
  34. Soeda, S.; Honda, O.; Shimeno, H.; Nagamatsu, A. Sphingomyelinase and cell-permeable ceramide analogs increase the release of plasminogen activator inhibitor-1 from cultured endothelial cells. Thromb. Res. 1995, 80, 509–518.
  35. Soeda, S.; Tsunoda, T.; Kurokawa, Y.; Shimeno, H. Tumor necrosis factor-alpha-induced release of plasminogen activator inhibitor-1 from human umbilical vein endothelial cells: Involvement of intracellular ceramide signaling event. Biochim. Biophys. Acta 1998, 1448, 37–45.
  36. Keul, P.; Peters, S.; von Wnuck Lipinski, K.; Schroder, N.H.; Nowak, M.K.; Duse, D.A.; Polzin, A.; Weske, S.; Graler, M.H.; Levkau, B. Sphingosine-1-Phosphate (S1P) Lyase Inhibition Aggravates Atherosclerosis and Induces Plaque Rupture in ApoE(-/-)Mice. Int. J. Mol. Sci. 2022, 23, 9606.
  37. Dressler, K.A.; Mathias, S.; Kolesnick, R.N. Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. Science 1992, 255, 1715–1718.
  38. Modur, V.; Zimmerman, G.A.; Prescott, S.M.; McIntyre, T.M. Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J. Biol. Chem. 1996, 271, 13094–13102.
  39. McEver, R.P.; Moore, K.L.; Cummings, R.D. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J. Biol. Chem. 1995, 270, 11025–11028.
  40. Haimovitz-Friedman, A.; Cordon-Cardo, C.; Bayoumy, S.; Garzotto, M.; McLoughlin, M.; Gallily, R.; Edwards, C.K., 3rd; Schuchman, E.H.; Fuks, Z.; Kolesnick, R. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J. Exp. Med. 1997, 186, 1831–1841.
  41. Escargueil-Blanc, I.; Andrieu-Abadie, N.; Caspar-Bauguil, S.; Brossmer, R.; Levade, T.; Negre-Salvayre, A.; Salvayre, R. Apoptosis and activation of the sphingomyelin-ceramide pathway induced by oxidized low density lipoproteins are not causally related in ECV-304 endothelial cells. J. Biol. Chem. 1998, 273, 27389–27395.
  42. Harada-Shiba, M.; Kinoshita, M.; Kamido, H.; Shimokado, K. Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J. Biol. Chem. 1998, 273, 9681–9687.
  43. Holopainen, J.M.; Lehtonen, J.Y.; Kinnunen, P.K. Lipid microdomains in dimyristoylphosphatidylcholine-ceramide liposomes. Chem. Phys. Lipids 1997, 88, 1–13.
  44. Holopainen, J.M.; Lemmich, J.; Richter, F.; Mouritsen, O.G.; Rapp, G.; Kinnunen, P.K. Dimyristoylphosphatidylcholine/C16:0-ceramide binary liposomes studied by differential scanning calorimetry and wide- and small-angle x-ray scattering. Biophys. J. 2000, 78, 2459–2469.
  45. Schissel, S.L.; Tweedie-Hardman, J.; Rapp, J.H.; Graham, G.; Williams, K.J.; Tabas, I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 1996, 98, 1455–1464.
  46. Chatterjee, S.B.; Dey, S.; Shi, W.Y.; Thomas, K.; Hutchins, G.M. Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Glycobiology 1997, 7, 57–65.
  47. Edsfeldt, A.; Duner, P.; Stahlman, M.; Mollet, I.G.; Asciutto, G.; Grufman, H.; Nitulescu, M.; Persson, A.F.; Fisher, R.M.; Melander, O.; et al. Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation. Arter. Thromb. Vasc. Biol. 2016, 36, 1132–1140.
  48. Jiang, X.C.; Paultre, F.; Pearson, T.A.; Reed, R.G.; Francis, C.K.; Lin, M.; Berglund, L.; Tall, A.R. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arter. Thromb. Vasc. Biol. 2000, 20, 2614–2618.
  49. Gao, X.; Ke, C.; Liu, H.; Liu, W.; Li, K.; Yu, B.; Sun, M. Large-scale Metabolomic Analysis Reveals Potential Biomarkers for Early Stage Coronary Atherosclerosis. Sci. Rep. 2017, 7, 11817.
  50. Hilvo, M.; Simolin, H.; Metso, J.; Ruuth, M.; Oorni, K.; Jauhiainen, M.; Laaksonen, R.; Baruch, A. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. Atherosclerosis 2018, 269, 159–165.
  51. Croyal, M.; Kaabia, Z.; Leon, L.; Ramin-Mangata, S.; Baty, T.; Fall, F.; Billon-Crossouard, S.; Aguesse, A.; Hollstein, T.; Sullivan, D.R.; et al. Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD? Diabetes Metab. 2018, 44, 143–149.
  52. Poss, A.M.; Maschek, J.A.; Cox, J.E.; Hauner, B.J.; Hopkins, P.N.; Hunt, S.C.; Holland, W.L.; Summers, S.A.; Playdon, M.C. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. J. Clin. Invest. 2020, 130, 1363–1376.
  53. Tu, C.; Xie, L.; Wang, Z.; Zhang, L.; Wu, H.; Ni, W.; Li, C.; Li, L.; Zeng, Y. Association between ceramides and coronary artery stenosis in patients with coronary artery disease. Lipids Health Dis. 2020, 19, 151.
  54. Mantovani, A.; Bonapace, S.; Lunardi, G.; Canali, G.; Dugo, C.; Vinco, G.; Calabria, S.; Barbieri, E.; Laaksonen, R.; Bonnet, F.; et al. Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. Diabetes Metab. 2020, 46, 150–157.
  55. Hilvo, M.; Meikle, P.J.; Pedersen, E.R.; Tell, G.S.; Dhar, I.; Brenner, H.; Schottker, B.; Laaperi, M.; Kauhanen, D.; Koistinen, K.M.; et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur. Heart J. 2020, 41, 371–380.
  56. Wang, D.D.; Toledo, E.; Hruby, A.; Rosner, B.A.; Willett, W.C.; Sun, Q.; Razquin, C.; Zheng, Y.; Ruiz-Canela, M.; Guasch-Ferre, M.; et al. Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevencion con Dieta Mediterranea). Circulation 2017, 135, 2028–2040.
  57. Meeusen, J.W.; Donato, L.J.; Bryant, S.C.; Baudhuin, L.M.; Berger, P.B.; Jaffe, A.S. Plasma Ceramides. Arter. Thromb. Vasc. Biol. 2018, 38, 1933–1939.
  58. Peterson, L.R.; Xanthakis, V.; Duncan, M.S.; Gross, S.; Friedrich, N.; Volzke, H.; Felix, S.B.; Jiang, H.; Sidhu, R.; Nauck, M.; et al. Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. J. Am. Heart Assoc 2018, 7.
  59. Pan, W.; Yu, J.; Shi, R.; Yan, L.; Yang, T.; Li, Y.; Zhang, Z.; Yu, G.; Bai, Y.; Schuchman, E.H.; et al. Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes. Coron Artery Dis. 2014, 25, 230–235.
  60. Vasile, V.C.; Meeusen, J.W.; Medina Inojosa, J.R.; Donato, L.J.; Scott, C.G.; Hyun, M.S.; Vinciguerra, M.; Rodeheffer, R.R.; Lopez-Jimenez, F.; Jaffe, A.S. Ceramide Scores Predict Cardiovascular Risk in the Community. Arter. Thromb. Vasc. Biol. 2021, 41, 1558–1569.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback